Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Fujitsu and MIT's Center for Brains, Minds, and Machines Develop AI Technology Inspired by the Human Brain Able to Recognize Unseen Data with High Accuracy
Fujitsu Limited and the Center for Brains, Minds and Machines (CBMM) headquartered at the Massachusetts Institute […]
Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment
Aichi Cancer Center and Fujitsu Limited today announced the development of an AI solution able […]
Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease
Fujitsu Limited today announced that it has started joint clinical research with the University of […]
Fujitsu Launches Solution Which Supports Cloud-based Epic EPRs
Fujitsu has launched a solution which will allow NHS trusts and other healthcare organisations in […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more